Developing a Phosphospecific IHC Assay as a Predictive Biomarker for Topoisomerase I Inhibitors

Koji Ando, Yara Hamade Tohme, Adithi Srinivasiah, Julian Taylor-Parker, Yevgeniya Harrington, Ankur K. Shah, Eiji Oki, Mohan Brahmandam, Ajit K. Bharti
  • Journal of Histochemistry & Cytochemistry, March 2018, SAGE Publications
  • DOI: 10.1369/0022155418766503

Predictive biomarker for irinotecan and topotecan class of drug.

What is it about?

The publication describes the technology of an IHC based test that has the potential to predict the response of a class of cancer drug. The commonly used drugs in this class is topotecan and irinotecan for gastric, colon, ovary and pancreatic cancer.

Why is it important?

This test will an important tool for oncologist to identify the responder patients for this class of drug. An important test in the field of personalized medicine.

Perspectives

Ajit Bharti (Author)
Boston University

This test is based on the basic understanding of drug resistance mechanism of this class of drug. This IHC based test is very unique in many ways and will be very helpful for the patients.

Read Publication

http://dx.doi.org/10.1369/0022155418766503

The following have contributed to this page: Ajit Bharti

In partnership with: